Currently browsing tag

companies

Hollande to meet ministers over Alstom’s plans for Belfort plant

French President Francois Hollande will meet Prime Minister Manuel Valls and ministers in charge of economic and transport policy on Monday morning to discuss trainmaker Alstom's sudden decision to scale down its Belfort plant, the president's office said. Alstom said on Wednesday it planned to stop making trains at Belfort and transfer production to its plant in Reichshoffen in eastern France by the end of 2018. Valls said on Sunday Alstom's decision was unacceptable.

Exclusive: Top U.S. airlines offer to re-assign crew from Zika-hit routes

Top U.S. airlines United and Delta have offered to re-assign certain flight crew concerned about contracting the Zika virus from routes to Latin America and the Caribbean, the companies told Reuters on Wednesday. In an internal memo on Jan. 28, seen by Reuters, United said expectant flight attendants as well as those seeking to become pregnant could switch routes to avoid Zika-affected regions without repercussions. The airline has similar options available for pilots, said Charles Hobart, spokesman for parent United Continental Holdings Inc. Delta Air Lines Inc has also let flight attendants and pilots switch assignments since Jan. 17, and “a small number of crew members have swapped trips to date,” spokesman Morgan Durrant told Reuters.

Emotions Impact Your Work — So Why Don’t Companies Take Mental Health Seriously?

This story is part of our monthlong “Work Well” initiative, which focuses on thriving in the workplace. You can find more stories from this project here.One somewhat unfortunate reality of living in the United States is that health care is inexorably tied up with employment, for better or for worse.On the plus side, employers generally…

Baxalta in deal to expand immuno-oncology business

(Reuters) – Drugmaker Baxalta Inc has signed a deal with privately held Symphogen under which the companies will develop immuno-oncology drugs to treat rare cancers. The deal with Symphogen comes as Baxalta approaches the final stages of negotiating a potential sale to rare diseases drugmaker Shire Pharmaceuticals. It would include a cash component of about $20 per share, with the rest of it paid in Shire stock, said the sources, asking not to be identified because the negotiations are confidential.